Annovis Bio Inc. (ANVS) – Company Press Releases
-
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
-
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
-
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
-
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
-
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
-
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
-
Annovis Bio to Participate in the 139th Yale CEO Summit
-
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
-
Annovis Bio Appoints Andrew Walsh as Vice President Finance
-
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
-
Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients
-
Annovis Bio Announces Pricing of $7.5 Million Public Offering
-
Annovis Bio Announces Launch of Proposed Public Offering
-
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
-
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
-
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
-
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
-
Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
-
Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
-
Annovis Bio Announces the Filing of a Groundbreaking Patent
-
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Bo
-
Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace
-
Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
-
Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans
-
ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST
-
ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST
-
ANNOVIS BIO TO HOLD LIVE WEBCAST TO REVIEW ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE CLINICAL PROGRAMS
-
ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION
-
ANNOVIS BIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
-
TheracosBio Announces the Appointments of Jim Greenwood to Board of Directors and Jeff McGroarty as Chief Financial Officer
-
Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
-
Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses
-
ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE
-
Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team
-
Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update
-
Annovis Bio to Present at the 2022 ThinkEquity Investor Conference
-
Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease
-
Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease
-
Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference
-
Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases
-
Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders
-
Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer
-
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease
-
Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update
-
Annovis Bio to Participate on Alzheimer's Association International Conference Panel
-
Annovis Bio to Present at the Alzheimer's Association International Conference
-
Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease
-
Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections
-
Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
Back to ANVS Stock Lookup
